TP53 and nasopharyngeal carcinoma: SALL4 is a potential target for the development of radiosensitizers, since it was shown in a study of nasopharyngeal carcinoma (NPC) to produce radioresistance through the ATM/Chk2/p53 pathway and its downstream apoptosis-relevant proteins [35].